Overview.
Overview.At Shift Bioscience, our mission is to safely reverse aging by cell rejuvenation, reducing cell age without changing cell identity.
Operating at the nexus of single cell sequencing, aging clocks and virtual cells, Shift’s proprietary single cell clock (AC3) leverages the efficiency of virtual cells to compress centuries of real world experiments into months.
Shift is compressing centuries of real-world experiments into months.
Shift Bioscience was founded in 2017 by Dr Daniel Ives, CEO, and Dr Brendan Swain, CSO, with research facilities at the University of Cambridge, a computational group based in Toronto, Canada, and a drug development team that brings experience from Alnylam, Moderna and GSK.
Leadership.
Investors.
